This is not Li Miaomiao's first visit to England. He had been to Cambridge and Oxford during high school holidays.
The feeling of coming to England this time is different from the last time. This time I came with a goal. Kechuang Biotech wants to acquire an AI chip company in England and build an AI chip R&D center in England based on it.
Secondmind is only the first target of Kechuang Biotech, and there are several other companies as alternatives.
This was also the first time he went abroad after the global epidemic spread. Li Miaomiao took a deep breath after getting off the plane. She was almost short of oxygen while wearing N95 on the plane.
"Everyone go through the prepared materials again after arriving at the hotel today, so there won't be any mistakes tomorrow."
Li Miaomiao specifically asked her to be responsible for this trip to England because she wanted to stop by the Lion City on her way back and visit Zheng Li.
"We are a biopharmaceutical company in China and hope to acquire your company. We will not interfere with the normal operations of the company in the first three years after acquiring the company."
The reason why Gouchang is more popular than Ahli in the investment community is that Gouchang rarely interferes in the operations of its investment companies, while Ahli likes to participate in the operations of investment companies and replaces the executives of its investment companies with Ahli. of employees.
In the investment circle, Ali is much more domineering than Goose Factory.
"We will only give you advice on AI chips and algorithms."
"The benefits of employees and executives will remain unchanged."
"This is the information from Science and Technology Biotech, you can take a look."
As a global leader in the field of brain-computer connection, Kechuang Biotechnology is still well-known.
Although the specific company name may not be named, when it comes to the Chinese company that specializes in brain-computer connection with mobile phones and endorphins, foreigners can instantly understand it.
Endorphins are as well-known in the field of biomedicine as brain-computer connections.
After the simultaneous interpreter translated Li Miaomiao's words, the chairman of Secondmind nodded: "Okay, let me take a look first."
The conference room was quiet except for the rustling of pages.
"I do not deny that Kechuang Biotech is an outstanding company and has made unique contributions in its own field."
"But we are curious, why does Kechuang Biotech want to acquire SecondMind? From the company's information, we can see that there is no overlap in our fields."
"SecondMind mainly produces AI algorithms and AI chips related to autonomous driving, while Kechuang Biotech seems to be doing brain-computer connection in addition to biomedicine."
"Your company acquired us, and I feel there is very little overlap and complementarity."
"So why should we accept your acquisition?"
Regarding the other party's embarrassment, Li Miaomiao was very calm:
"Secondmind has not accepted new investment since it started its B-round investment in 2019. Moreover, the valuation of Secondmind's B-round investment in 19 was 100 million yuan, but the actual funds raised were only 24 million yuan."
"Affected by the epidemic in the past two years, the price of chip foundry has been rising year by year, and labor costs are also rising. I wonder how long Secondmind can last without investment?"
"As an AI chip company in England, Graphcore received a large amount of funding last year, and DeepMind has been backed by Google since 2014."
"How can SecondMind survive? The revenue from cooperation with Mazda is limited, so it should not be able to support the company's further development."
England is a powerhouse for AI research. Over the years, multinational giants have continued to invest in English AI companies, but there are very few Chinese companies.
HP announced the acquisition of Autonomy. Amazon acquired true knowledge; in 2014, Google acquired deepmind, dark blue labs, and vision factory, Apple acquired vocaliq, Microsoft acquired swiftkey, and twitter acquired magicpony.
The ones behind are all companies in the field of artificial intelligence in England, not all AI chips.
"We have sufficient funds, and other investment institutions have expressed their willingness to participate in secondmind's C-round investment."
“We will soon advance SecondMind’s C-round fundraising, and giants like Kechuang Biotech are very welcome to participate.”
They welcome investment, but don't want to be acquired.
Li Miaomiao is very suspicious. No one has invested in you in the past two years. As soon as we said we wanted to acquire it, someone came to invest?
On second thought, Cheng Gang told him when she was on the way that Goldman Sachs and IDG also wanted to participate in SecondMind's investment.
"Do IDG and Goldman Sachs want to invest in you?"
The other party nodded: "Now that you know, I have nothing to hide."
"IDG and Goldman Sachs have signed share transfer memorandums with our shareholders respectively, and the two investment institutions have stated that they will help us start the C round of fundraising as soon as possible."
"Among them, idg and Goldman Sachs will lead the investment."
Li Miaomiao thought to herself that these investment institutions were really shameless. They knew that Kechuang Biotech was going to acquire Secondmind and they acted more decisively than they did.
In this regard, Kechuang Biotech still has many shortcomings. If it were a goose factory, it would have completed this matter long ago without anyone noticing.
The first meeting ended in a hurry, and Li Miaomiao felt that she needed to review the specific circumstances of the matter.
Then figure out the intentions of idg and Goldman Sachs.
Currently, the only shareholders of SecondMind are Goldman Sachs, IDG, Goose Factory, Cambridge University Investment Fund and its founders.
The shareholding structure is simple, but there is no fuel-saving light in it.
...
Kechuang Biotechnology issued an announcement at 0:00 a.m. on New Year's Day. The content of the announcement was to the effect:
"Kechuang Biotechnology has completed the research and development of brain-computer connection for mobile phones of all English speakers. The patent is being registered globally, and patent licensing negotiations have begun simultaneously with major mobile phone manufacturers."
It also explains that the licensing price of English-language brain-computer connection patents needs to be adjusted. It will not be like the Chinese-language patent licensing price of 200 yuan per mobile phone.
As soon as the news came out, the top ten science and technology biotech stocks were quickly pushed to the first place:
"Good landing, let's dive high!"
There are many such comments. Not only is there some truth to diving at a high level, but people in the stock market have a mentality that if the company is doing well and I don’t have a position, then I will be bearish without thinking.
"The current price of Kechuang Biotechnology, which is just over 2,000 yuan, is not high. In the short term, it is expected to reach 3,000 yuan."
Currently, Kechuang Biotechnology and Moutai are the only two companies in the A-share market whose stock prices exceed 2,000 yuan.
Liquor companies have been rising, so much so that stockholders joked that China’s technology stocks are Maotai Technology and Luzhou Technology.
Most investors are still happy to see technology stocks represent China's securities exchange market rather than wine companies.
“The patent authorization of English-language brain-computer connection to mobile phones will release at least RMB 6 billion in profits for Kechuang Biotech in 2022. This is based on the current patent authorization price.
If the price is renegotiated, the net profit will still rise.
Profit is not the most important thing, but what is more critical is that Kechuang Biotech was the first to issue an announcement, showing that it is still the strongest company in the field of brain-computer connection.
Kechuang Bio's revenue in the field of brain-computer connection is the combined revenue of all other companies in the field of brain-computer connection.
For such a company with core monopoly technology and maintaining high growth and high profits, what reason is there not to build a position? "
